Evaluation of Plasma Creatine Phosphokinase (CPK) Level Following a Single Injection of Methotrexate as a Predicator of Treatment Success in Ectopic Pregnancy
Abstract
Objective: To evaluate the plasma creatine phosphokinase (CPK) level after a single injection of methotrexate (MTX) as a predictor of treatment success in ectopic pregnancy (EP).
Materials and methods: In this prospective study, seventy nine women older than 18 years treated with methotrexate for ectopic pregnancy were evaluated for CPK and β-subunit of human chorionic gonadotropin (βhCG) levels, while they received intramuscular MTX at a dose of 50 mg/m2. The day of injection was considered as day 1 (D1). CPK level on D1 was compared between the group 1(as treatment success group), treated by a single MTX injection, and the group 2, treated by two or three MTX injections or by surgery.
Results:The success rate of MTX treatment was 58 (73.3%). The mean of CPK was higher in treatment success group (group1) than failure group (group 2) (71.98 ± 15.711 vs. 64.43 ± 15.898), but the difference was not significant (p=0.06). The mean of βhCG was significantly lower in treatment success group (group 1) than failure group (group 2) (1187.52±631.45 vs. 1663.87±1096.845; p=0.01). Ultrasonographic findings of EP were seen in 63 patients, while the means of βHCG and CPK were higher in these patients than those with normal ultrasonography, but difference was not significant (p=0.37 and p=0.24, respectively).
Conclusion:The sample was not large enough to indicate a significant difference in the CPK level, which can be considered as an indicator for differentiating between the successful and unsuccessful treatment groups. Moreover, the present study did not show any relation between initial β-hCG and CPK serum levels, so our findings indicate that they are not possibly considered as two independent biomarkers in ectopic pregnancy.
Kriebs JM, Fahey JO. Ectopic pregnancy. J Midwifery Womens Health 2006;51:431–9.
Condous G. Ectopic pregnancy-risk factors and diagnosis. Aust Fam Physician 2006;35:854–7.
Barnhart KT. Clinical practice. Ectopic pregnancy. N Engl J Med 2009;361:379–87.
Hoover KW, Tao G, Kent CK. Trends in the diagnosis and treatment of ectopic pregnancy in the United States. Obstet Gynecol 2010;115:495–502.
Barnhart KT, Gosman G, Ashby R, Sammel M. The medical management of ectopic pregnancy: a meta analysis comparing ‘‘single dose’’ and ‘‘multidose’’ regimens. Obstet Gynecol 2003;101:778–84.
Lipscomb GH, Givens VA, Meyer NL, Bran D. Previous ectopic pregnancy as a predictor of failure of systemic methotrexate therapy. FertilSteril 2004;81:1221- 4.
Lipscomb GH, Givens VM, Meyer NL, Bran D. Comparison of multidose and single-dose methotrexate protocols for the treatment of ectopic pregnancy. Am J Obstet Gynecol 2005;192:1844–8.
Corsan GH, Karacan M, Qasim S, Bohrer MK, Ransom MX, Kemmann E. Identification of hormonal parameters for successful systemic single-dose methotrexate therapy in ectopic pregnancy. Hum Reprod 1995;10:2719-22.
Tanaka T, Hayashi H, Kutsuzawa T, Fujimoto S, Ichinoe K. Treatment of interstitial ectopic pregnancy with methotrexate: report of a successful case. Fertil Steril 1982;37:851–2.
Ory SJ, Villanueva AL, Sand PK, Tamura RK. Conservative treatment of ectopic pregnancy with methotrexate. Am J Obstet Gynecol 1986;154:1299–306.
Stovall TG, Ling FW, Gray LA, Carson SA, Buster JE. Methotrexate treatment of unruptured ectopic pregnancy: a report of 100 cases. Obstet Gynecol 1991;77:749–53.
Stovall TG, Ling FW. Single-dose methotrexate: an expanded clinical trial. Am J Obstet Gynecol 1993;168:1759–62.
ShalevE, Peleg D, Bustan M, Romano S, Tsabari A. Limited role for intratubal methotrexate treatment of ectopic pregnancy. Fertil Steril1995;63:20-4.
Stika CS, Anderson L, Frederiksen MC. Single- dose methotrexate for the treatment of ectopic pregnancy: Northwestern Memorial Hospital three-year experience. Am J ObstetGynecol 1996;174:1840-6.
Lipscomb GH, McCord ML, Stovall TG, Huff G,PorteraSG, LingFW. Predictors of success of methotrexate treatment in women with tubal ectopic pregnancies. N Engl J Med 1999;341:1974-8
DeveliogluOH, Askalli C, Uncu G, SamliB,Daragenli O. Evaluation of serum creatine kinase in ectopic pregnancy with reference to tubal status and histopathology. BJOG 2002;109:121–8.
Birkhahn RH, Gaeta TJ, Leo PJ, Bove JJ. The utility of maternal creatine kinase in the evaluation of ectopic pregnancy. Am J Emerg Med 2000;18:695–7.
Katsikis I, Rousso D, Farmakiotis D, Kourtis A, Diamanti- Kandarakis E, Zournatzi-Koiou V, et al. Creatine phosphokinase in ectopic pregnancy revisited: significant diagnostic value of its MB and MM isoenzyme fractions. Am J ObstetGynecol 2006;194:86–91.
Gnisci A, Rua S, Courbiere B, Cravello L, Gamerre M, Agostini A Plasma creatine phosphokinase level may predict successful treatment after a single injection of methotrexate for ectopic pregnancy. Fertil Steril 2011;95:2131–3.
Asgharnia M, Faraji R, Mirblouk F, Atrkar Roshan Z, Parvizi A. Evaluation of serum creatine phosphokinase in diagnosis of tubal ectopic pregnancy compared with intrauterine pregnancy and threatened abortion. Iranian Journal of Reproductive Medicine 2012; 10: 303-6.
Saha PK, Gupta I, Ganguly NK. Evaluation of serum creatine kinase as a diagnostic marker for tubal pregnancy.Aust N Z J ObstetGynaecol 1999; 39: 366-7.
Lavie O, Beller U, Neuman M, Ben-Chetrit A, Gottcshalk-Sabag S, Diamant YZ. Maternal serum creatine kinase: a possible predictor of tubal pregnancy. Am J Obstet Gynecol 1993; 169: 1149-50.
Birkhahn RH, Gaeta TJ, Paraschiv D, Bove JJ, Suzuki T, Katoh H, et al. Serum levels of myoglobin, creatine phosphokinase, and smooth muscle heavy-chain myosin in patients with ectopic pregnancy. Ann Emerg Med 2001; 38: 628-32.
Cartwright J, Duncan WC, Critchley HO, Horne AW. Serum biomarkers of tubal ectopic pregnancy: current candidates and future possibilities. Reproduction 2009; 138: 9-22.
Nowak-Markwitz E, Michalak M, Olejnik M, Spaczynski M. Cutoff value of human chorionic gonadotropin in relation to the number of methotrexate cycles in the successful treatment of ectopic pregnancy. Fertil Steril 2009;92:1203–7.
Colins J, Barnhart KT. Establishing a human chorionic gonadotropin cutoffto guide methotrexate treatment of ectopic pregnancy:a systematic review. Fertil Steril 2007; 87:481– 4.
| Files | ||
| Issue | Vol 7, No 4 (December 2013) | |
| Section | Original Articles | |
| Keywords | ||
| CPK Ectopic Pregnancy Methotrexate Treatment | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
